These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 22459734)

  • 61. Antibiotic resistance mechanisms in M. tuberculosis: an update.
    Nguyen L
    Arch Toxicol; 2016 Jul; 90(7):1585-604. PubMed ID: 27161440
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mycobacterium tuberculosis drug resistance: a call to action.
    Sudre P; Cohn DL
    Int J Tuberc Lung Dis; 1998 Aug; 2(8):609-11. PubMed ID: 9712272
    [No Abstract]   [Full Text] [Related]  

  • 63. [Reasons for drug-resistant tuberculosis emergence].
    Tu DH
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):403-5. PubMed ID: 17673006
    [No Abstract]   [Full Text] [Related]  

  • 64. [Respiratory fluoroquinolones and pulmonary tuberculosis treatment when the main drugs are ineffective].
    Lazareva NB; Khaĭmenova TIu; Khaĭmenov AIa
    Antibiot Khimioter; 2008; 53(5-6):14-20. PubMed ID: 19069177
    [No Abstract]   [Full Text] [Related]  

  • 65. A Collaborative Approach for "ReSeq-ing" Mycobacterium tuberculosis Drug Resistance: Convergence for Drug and Diagnostic Developers.
    Schito M; Dolinger DL
    EBioMedicine; 2015 Oct; 2(10):1262-5. PubMed ID: 26629499
    [No Abstract]   [Full Text] [Related]  

  • 66. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.
    Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE
    Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Linezolid in the treatment of drug-resistant tuberculosis: the way forward?
    Yew WW; Lange C
    Int J Tuberc Lung Dis; 2014 Jun; 18(6):631-2. PubMed ID: 24903928
    [No Abstract]   [Full Text] [Related]  

  • 68. Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules.
    Bolhuis MS; van der Werf TS; Kerstjens HAM; de Lange WCM; Alffenaar JC; Akkerman OW
    Eur Respir J; 2019 Dec; 54(6):. PubMed ID: 31439686
    [No Abstract]   [Full Text] [Related]  

  • 69. Representations on adherence to the treatment of Multidrug-Resistant Tuberculosis.
    Ferreira KR; Orlandi GM; Silva TCD; Bertolozzi MR; França FOS; Bender A
    Rev Esc Enferm USP; 2018 Dec; 52():e03412. PubMed ID: 30569960
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Fluoroquinolones and dairy intake: dogma or evidence? Considerations on the short-course regimen for children.
    Monedero I; Macias CP
    Int J Tuberc Lung Dis; 2017 Dec; 21(12):1316-1317. PubMed ID: 29297456
    [No Abstract]   [Full Text] [Related]  

  • 71. Fatal Lure of Look-Back Studies in Explaining Pharmacological Events Such as Acquired Drug Resistance in Patients With Multidrug-Resistant Tuberculosis.
    Pasipanodya J; Srivastava S; Gumbo T
    J Infect Dis; 2015 Jul; 212(1):166-7. PubMed ID: 25649174
    [No Abstract]   [Full Text] [Related]  

  • 72. MDR tuberculosis and non-compliance with therapy.
    Cox H; Hughes J; Ford N; London L
    Lancet Infect Dis; 2012 Mar; 12(3):178; author reply 178-9. PubMed ID: 22361422
    [No Abstract]   [Full Text] [Related]  

  • 73. A step forward in the treatment of multidrug-resistant tuberculosis.
    Ridzon R; Castro KG
    Int J Tuberc Lung Dis; 2019 May; 23(5):533-534. PubMed ID: 31097059
    [No Abstract]   [Full Text] [Related]  

  • 74. [Is it necessary to add a fourth drug to the initial treatment of tuberculosis?].
    Torres L; Pérez JB; Lezcano MA; Revillo MJ
    Med Clin (Barc); 2001 May; 116(16):637-8. PubMed ID: 11412655
    [No Abstract]   [Full Text] [Related]  

  • 75. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study--authors' response.
    Prahl JB; Johansen IS; Cohen AS; Frimodt-Møller N; Andersen ÅB
    J Antimicrob Chemother; 2015 Jan; 70(1):321-2. PubMed ID: 25246439
    [No Abstract]   [Full Text] [Related]  

  • 76. [Diagnosis, treatment and prevention of infectious diseases. Topics: III. Various problems in antimicrobial agents; 3. Advances in antituberculosis drugs].
    Tsuyuguchi K
    Nihon Naika Gakkai Zasshi; 2013 Nov; 102(11):2922-7. PubMed ID: 24450130
    [No Abstract]   [Full Text] [Related]  

  • 77. Comment on: Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.
    Pasipanodya JG; Srivastava S; Gumbo T
    J Antimicrob Chemother; 2015 Jan; 70(1):320-1. PubMed ID: 25182065
    [No Abstract]   [Full Text] [Related]  

  • 78. Dried blood spot analysis combined with limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs.
    Alffenaar JW
    J Infect Dis; 2012 Jun; 205(11):1765-6; author reply 1766. PubMed ID: 22459734
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.